In a potentially crippling move, a judge has thrown out the expert testimony of a doctor for the plaintiffs in the multidistrict products liability litigation over Accutane, a development that may lead to the dismissal of all cases alleging that Roche Holding AG's acne drug causes irritable bowel syndrome.
Forest Laboratories Inc. has urged a judge to deny the request of one of the plaintiffs in the multidistrict litigation involving blockbuster antidepressant drugs Celexa and Lexapro, arguing that time limitations prevent the addition of a Forest subsidiary to the complaint.
Having been shot down previously in a bid for discovery over a new theory about Prempro in the multidistrict products liability litigation over the hormone drug, plaintiffs' attorneys have made a new bid for documents related to progestin-free products.
Having lost another battle in its war over the much-maligned painkiller, Merck & Co. must pay $4 million to plaintiffs' attorneys in a New Jersey case that alleged it hid information from doctors about the heart attack risks of Vioxx.
Williams Bailey LLP filed more product liability lawsuits than any other firm last year, targeting Fortune 500 companies in hundreds of suits, our survey of the plaintiffs bar shows.
Retractable Technologies Inc. has filed a lawsuit against Becton Dickinson and Co. accusing the medical technology giant of patent infringement, false advertising and anti-competitive conduct.
Nutriceutical company Confidence Inc. has voluntarily recalled one of its supplement products after the U.S. Food and Drug Administration found it contained undeclared traces of a drug used to treat erectile dysfunction, the company said Thursday.
The U.S. Attorney's Office in New Jersey has dropped a securities fraud charge against Bristol-Myers Squibb Co., saying the drug maker has turned itself around in the past two years.
A Tyco International Ltd. subsidiary under attack by Purdue Pharma LP for allegedly infringing three patents for painkiller OxyContin has responded to Purdue's amended complaint, asking the court to declare that the patents are unenforceable due to inequitable conduct.
A veterinarian pharmaceutical company has filed a lawsuit seeking declaratory judgment against Pfizer and a veterinarian supply company, alleging the companies are restraining the sale of its canine skin infection drug.
The judge overseeing the massive marketing, sales practices and products liability litigation over anti-inflammatory pain medications Celebrex and Bextra has dismissed a slew of claims.
In a move to defend its claim to the U.S. market, Sanofi-Aventis U.S. LLC sued Sandoz Inc. Thursday for allegedly infringing a patent for its popular colon cancer drug, which a handful of other countries have already rejected.
The State of Mississippi has lost the most recent round in its battle with drug maker Ely Lilly & Co. over the schizophrenia and bipolar disorder treatment Zyprexa, after a federal judge refused to certify for appeal a recent decision denying Mississippi's motion to remand the case back to state court.
Citing the public's First Amendment rights to view court documents, Bloomberg LP has filed a motion to unseal Boston Scientific Corp. filings which were used in an attempt to throw out a product liability case regarding allegedly defective implantable heart defibrillators.
Over the past decade, drug lawsuits have become the blockbusters of product-liability litigation. But the future of such litigation hinges on what becomes of the doctrine of regulatory preemption.
A massive case against Bausch & Lomb Inc. over a contact lens solution is continuing to build in state and federal courts, with some observers expecting it to end in a large settlement.
Direct purchasers of ulcer medicine Aciphex dismissed their class action antitrust lawsuit against Eisai Co. Ltd. on Wednesday following the Japanese pharmaceutical company's victory in a patent infringement case which essentially quashed the antitrust claims as well.
A survey of 402 psychiatrists funded by pharmaceutical maker Eli Lilly & Co. found that people with mental illness often stop taking their drugs or ask to be switched from a drug that is effectively treating them after seeing attorney advertisements for product liability suits.
While Merck may already have its hands full trying to fend off thousands of Vioxx suits, the company is quietly fighting another front in widening litigation over its osteoporosis drug Fosamax.
The French drug company Sanofi-aventis announced on Wednesday that a Food and Drug Administration advisory panel has voted unanimously not to recommend approving its new weight loss drug, citing concerns about its effectiveness and safety.